Lercapress

Enalapril maleate, the active ingredient in Lercapress, is an ACE inhibitor presented as an oral tablet for oral use. Lercapress also contains lercanidipine hydrochloride, a calcium‑channel blocker, and together they are indicated for the management of high blood pressure. GNH USA supplies Lercapress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercapress acts on the renin‑angiotensin system and vascular smooth‑muscle tone to lower elevated blood pressure. - Hypertension: provides sustained blood‑pressure reduction in patients with primary hypertension. - High‑risk hypertension: helps achieve target pressures in patients with additional cardiovascular risk factors. - Resistant hypertension: offers an additional mechanism when monotherapy is insufficient.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness: especially upon standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: markedly low blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hyperkalemia: elevated potassium levels. - Renal impairment: worsening kidney function. - Allergic rash: widespread skin eruption.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte balance: monitor potassium, especially if using potassium‑sparing agents. - History of angioedema: avoid in patients with prior episodes. - Pregnancy considerations: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lercapress may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Concurrent ACE inhibitor and ARB: increased risk of renal dysfunction and hyperkalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lercanidipine levels, leading to hypotension. - Potassium‑sparing diuretics or supplements: heighten hyperkalemia risk. Moderate Interactions (Monitor Closely): - Diuretics: may potentiate blood‑pressure lowering effects. - Lithium: can increase lithium concentrations. - NSAIDs: may blunt antihypertensive response. - Rifampin: may reduce enalapril effectiveness.